Treatment of Alzheimer's disease with clioquinol

Dementia and Geriatric Cognitive Disorders

Volumn 12, Issue 6, 2001, Pages 408-414

  Regland, Björn ^a   Lehmann, Werner ^a   Abedini, Iraj ^a   Blennow, Kaj ^a   Jonsson, Michael ^a   Karlsson, Ingvar ^a   Sjögren, Magnus ^a   Wallin, Anders ^a   Xilinas, Michel ^a   Gottfries, Carl Gerhard ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Clioquinol; Growth associated protein; Heavy metal ions; Tau protein

Indexed keywords

CALCIUM ION; CHELATING AGENT; CLIOQUINOL; COPPER ION; GROWTH ASSOCIATED PROTEIN; HEAVY METAL; ION; MAGNESIUM ION; TAU PROTEIN; ZINC ION;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD LEVEL; CEREBROSPINAL FLUID EXAMINATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DISEASE MARKER; DOSE CALCULATION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN SECRETION; SENILE PLAQUE; SINGLE BLIND PROCEDURE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHELATING AGENTS; CHELATION THERAPY; CLIOQUINOL; COPPER; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GAP-43 PROTEIN; HUMANS; MALE; MIDDLE AGED; TAU PROTEINS; TREATMENT OUTCOME; ZINC;

EID: 18444399243     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000051288     Document Type: Article

References (32)

1. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association) Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
2. 42 and phosphorylated tau protein as biomarker for Alzheimer's disease
3. Neurofibrillary pathology of Alzheimer's disease and other tauopathies
4. Primary structure and transcriptional regulation of GAP-43, a protein associated with nerve growth
5. Localization of the growth-associated phosphoprotein GAP-43 (B-50, F1) in the human cerebral cortex
6. Immunocytochemical detection of the growth-associated protein B-50 by newly characterized monoclonal antibodies in human brain and muscle
7. Growth-associated protein GAP-43 in the frontal cortex and in the hippocampus in Alzheimer's disease: An immunohistochemical and quantitative study
8. Alzheimer's disease: Initial report of purification and characterization of a novel cerebrovascular protein
9. Amyloid beta-binding protein in vitro and in normal human cerebrospinal fluid
10. Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains
11. Detection of pathological zinc accumulation in neurons: Methods for autopsy, biopsy, and cultured tissue
12. Dramatic aggregation of Alzheimer Aβ by Cu(II) is induced by conditions representing physiological acidosis
13. Hypothesis: Is Alzheimer's disease a metal-induced immune disorder?
14. Increased blood mercury levels in patients with Alzheimer's disease
15. Rapid induction of Alzheimer A beta amyloid formation by zinc
16. Clioquinol
17. The neuropathology of subacute myelo-optico-neuropathy (SMON) in the humans: With special reference to the quinoform intoxication
18. Changes in uptake of vitamin B12 and trace metals in brains of mice treated with clioquinol
19. "Mini-mental state". A practical method for grading the cognitive state of patients for clinicians
20. The Alzheimer's disease assessment scale: An instrument for assessing treatment efficacy
21. A new rating scale for dementia syndromes
22. Development of a specific diagnostic test for measurement of B-amyloid (1-42) in CSF
23. Cerebrospinal fluid B amyloid (1-42) in Alzheimer's disease: Differences between early- and late-onset Alzheimer's disease and stability during the course of disease
24. Tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer's disease?
25. Combination of tau/phospho-tau with other biochemical markers for Alzheimer CSF diagnosis and tau in CSF as marker for neurodegeneration
26. CSF levels of tau, B-amyloid42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging
27. Intramuscular desferrioxamine in patients with Alzheimer's disease
28. Clioquinol-Zinc chelate: A candidate causative agent of subacute myelo-optic neuropathy
29. CSF copper concentration, blood-brain barrier function, and coeruloplasmin synthesis during the treatment of Wilson's disease
30. Alzheimers disease/alcohol dementia: Association with zinc deficiency and cerebral vitamin B12 deficiency
31. Soluble pool of A beta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease